In our study, fruquintinib treatment led to the upregulation of E-cadherin and the downregulation of N-cadherin, vimentin, and MMP9, suggesting that it inhibits EMT and may reduce CRC cell motility and invasiveness. This evidence concerns the gene CDH1 and colorectal carcinoma.